OverviewSuggest Edit
Lipocine is a specialty pharmaceutical company developing pharmaceutical products using its oral drug delivery technology in the areas of men's and women's health. The Company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is LPCN 1021, an oral testosterone replacement therapy.
| Type | Public | |
| Founded | 1997 | |
| HQ | Salt Lake City, UT, US | Map |
| Website | lipocine.com |
Recent NewsAll News
- Thinking about buying stock in Verb Technology, Casper Sleep, Millendo Therapeutics, Lipocine, or Hepion Pharmaceuticals?
- Clarus Therapeutics Announces Comprehensive Settlement of Patent Litigation With Lipocine
- Lipocine To Present At The Raymond James Human Health Innovation Conference
- Thinking about buying stock in Mereo BioPharma, Lipocine, Lordstown Motors, Sorrento Therapeutics, or Axcella Health?
Key People/Management at Lipocine
Mahesh V. Patel
Chairman, President and Chief Executive Officer
Morgan Brown
Executive Vice President and Chief Financial Officer
Anthony DelConte
Chief Medical Director
Lipocine Office Locations
Lipocine has offices in Salt Lake City and Trenton
Salt Lake City, UT, US (HQ)
675 Arapeen Dr #202
Trenton, NJ, US
3150 Brunswick Pike #130
Lipocine Financials and Metrics
Lipocine Revenue
| USD | |
|---|---|
Net income (FY, 2020) | (21.0m) |
EBIT (FY, 2020) | (18.0m) |
Market capitalization (16-Jul-2021) | 111.2m |
Closing stock price (16-Jul-2021) | 1.3 |
Cash (31-Dec-2020) | 19.2m |
EV | 102.6m |
Lipocine's current market capitalization is $111.2 m.
Annual
Quarterly
| USD | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 428.0k | 165.0k | ||||||||||||||||||||||||
General and administrative expense | 2.2k | 3.3k | 5.7k | 3.2k | 6.3k | 1.2m | 1.9m | 1.0m | 871.8k | 1.1m | 1.1m | 1.7m | 4.4m | 3.2m | 1.4m | 1.8m | 2.0m | 2.7m | 1.7m | 1.7m | 930.1k | 1.2m | 1.4m | 1.4m | 2.1m | 2.0m |
R&D expense | 1.6m | 3.4m | 6.0m | 3.2m | 1.9m | 3.2m | 4.7m | 2.7m | 2.6m | 1.5m | 3.1m | 4.1m | 2.0m | 1.4m | 1.5m | 1.4m | 1.9m | 2.0m | 1.7m | 2.5m | 2.3m | |||||
Operating expense total | 2.2k | 3.3k | 5.7k | 3.2k | 6.3k | 2.8m | 5.3m | 7.0m | 4.1m | 3.0m | 4.3m | 6.5m | 7.1m | 5.9m | 3.3m | 5.0m | 6.2m | 4.8m | 3.1m | 3.2m | 2.4m | 3.1m | 3.4m | 3.1m | 4.6m | 4.2m |
Annual
Quarterly
| USD | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 17.9k | 3.4k | 622.0 | 458.0 | 10.0 | 36.8m | 41.8m | 34.2m | 31.7m | 24.8m | 38.3m | 23.9m | 14.1m | 12.4m | 4.7m | 6.9m | 16.6m | 9.3m | 8.6m | 1.6m | 4.8m | 8.2m | 3.7m | 6.7m | 15.1m | 13.8m |
Prepaid Expenses | 251.7k | 256.4k | 1.3m | 285.9k | 186.5k | 181.3k | 347.8k | 268.9k | 154.0k | 457.4k | 262.0k | 88.6k | 453.4k | 248.0k | 113.3k | 728.5k | 411.4k | 148.9k | 754.5k | 373.4k | 147.3k | |||||
Current Assets | 622.0 | 458.0 | 10.0 | 37.1m | 42.0m | 35.4m | 32.0m | 25.0m | 44.1m | 42.3m | 38.6m | 33.2m | 29.4m | 27.1m | 27.9m | 26.1m | 31.6m | 25.3m | 22.6m | 23.0m | 19.6m | 17.3m | 21.0m | 23.5m | ||
PP&E | 34.8k | 27.6k | 24.6k | 40.7k | 82.7k | 79.9k | 82.9k | 108.3k | 119.9k | 111.7k | 96.3k | 89.3k | 82.2k | 32.3k | 27.9k | 23.4k | 15.1k | 11.3k | 7.4k | 2.8k | 2.0k |
Annual
| USD | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | (76.7k) | (10.6m) | (20.4m) | (18.2m) | (19.0m) | (21.0m) | (11.7m) | (13.0m) | (21.0m) |
Depreciation and Amortization | 21.8k | 14.6k | 26.7k | 32.0k | 28.4k | 18.6k | 15.4k | 3.6k | |
Accounts Payable | 4.3k | 668.8k | (449.6k) | 200.8k | (261.2k) | 352.2k | 73.2k | 511.0k | 415.0k |
Cash From Operating Activities | (62.9k) | (8.6m) | (17.3m) | (15.4m) | (18.3m) | (16.7m) | (12.1m) | (11.7m) | (15.3m) |
Quarterly
| USD | Q1, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (4.8k) | (71.7k) | (3.2k) | (6.3k) | (6.2m) | (5.3m) | (12.2m) | (16.3m) | (3.0m) | (7.2m) | (13.6m) | (7.0m) | (12.8m) | (16.0m) | (4.9m) | (11.0m) | (15.7m) | (2.7m) | (6.0m) | (8.4m) | (3.2m) | (6.7m) | (9.7m) | (5.8m) | (12.1m) |
Depreciation and Amortization | 15.7k | 3.0k | 6.1k | 9.4k | 4.3k | 8.7k | 19.6k | 6.7k | 15.5k | 23.7k | 7.1k | 14.2k | 21.3k | 5.3k | 9.7k | 14.2k | 3.9k | 7.7k | 11.6k | 799.0 | 1.6k | ||||
Accounts Payable | (612.0) | 3.1k | 5.7k | 1.1m | (254.0k) | (385.2k) | (627.9k) | 73.3k | 30.1k | 150.6k | 570.1k | 482.0k | 357.9k | 607.6k | 867.9k | 557.9k | (209.7k) | (191.5k) | (358.1k) | (153.6k) | (555.2k) | 689.2k | 472.7k | (275.4k) | |
Cash From Operating Activities | (5.1k) | (62.8k) | (119.0) | (567.0) | (4.5m) | (3.5m) | (11.1m) | (13.6m) | (3.0m) | (6.9m) | (12.4m) | (6.5m) | (11.7m) | (15.7m) | (3.1m) | (7.8m) | (12.4m) | (3.7m) | (6.5m) | (9.8m) | (3.0m) | (5.6m) | (8.4m) | (3.4m) | (7.5m) |
Lipocine Cybersecurity Score
Lipocine Online and Social Media Presence
Lipocine's Trends
Lipocine News and Updates
July 15, 2021
Thinking about buying stock in Verb Technology, Casper Sleep, Millendo Therapeutics, Lipocine, or Hepion Pharmaceuticals?
NEW YORK, July 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VERB, CSPR, TPST, LPCN, and HEPA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
July 15, 2021
Clarus Therapeutics Announces Comprehensive Settlement of Patent Litigation With Lipocine
Clarus Therapeutics Inc. ("Clarus") and Lipocine, Inc. (“Lipocine”) agree to resolve all outstanding claims between the companies in the on-going intellectual property litigation (U. S. District Court for the District of Delaware) and patent interference (U. S. Patent & Trademark Office; USPTO) …
June 16, 2021
Lipocine To Present At The Raymond James Human Health Innovation Conference
SALT LAKE CITY, June 16, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Raymond James Human Health Innovation Conference. The conference will...
June 14, 2021
Thinking about buying stock in Mereo BioPharma, Lipocine, Lordstown Motors, Sorrento Therapeutics, or Axcella Health?
NEW YORK, June 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MREO, LPCN, RIDE, SRNE, and AXLA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
May 06, 2021
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2021
SALT LAKE CITY, May 6, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the first quarter ended March 31, 2021 and provided a corporate update. First Quarter...
December 09, 2020
Lipocine Announces Tentative Approval of TLANDO™
SALT LAKE CITY, Dec. 8, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA") has granted tentative approval to TLANDO, its oral...
Lipocine Blogs
Lipocine Frequently Asked Questions
When was Lipocine founded?
Lipocine was founded in 1997.
Who are Lipocine key executives?
Lipocine's key executives are Mahesh V. Patel, Morgan Brown and Anthony DelConte.
How many employees does Lipocine have?
Lipocine has 12 employees.
Who are Lipocine competitors?
Competitors of Lipocine include PhagePro, Akthelia and Bioiberica.
Where is Lipocine headquarters?
Lipocine headquarters is located at 675 Arapeen Dr #202, Salt Lake City.
Where are Lipocine offices?
Lipocine has offices in Salt Lake City and Trenton.
How many offices does Lipocine have?
Lipocine has 2 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies